Mitsubishi launches ALS drug Radicava in U.S.

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) launched Radicava edaravone in the U.S. to treat amyotrophic lateral sclerosis (ALS). The wholesale acquisition cost (WAC) of two 30 mg/100 mL IV infusion bags is $1,086. The recommended dose during the 28-day cycles is 60 mg. For the first cycle, patients receive a once-daily dose for 14 days, followed by a two-week drug-free period. For each additional cycle, patients receive a once-daily dose for 10 days within a 14-day period, followed by a two-week drug-free period...